Market introduction of psychedelics as a therapy looks promising. However, policy and regulatory issues concerning the drug class still exist.
This is the first time psilocybin has been produced from a prokaryotic organism.
Scientific and public opinion is slowly shifting for the potential usage of psilocybin in a variety of conditions. Can the same be said for recreational usage?
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.